ReviewCirculation. Cardiovascular imaging2018
Molecular Imaging in Drug Discovery and Development.
Review in Circulation. Cardiovascular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Fluorescent Labeling and Imaging of IL-22 mRNA-Loaded Lipid Nanoparticles.Bio-protocol · 2024Article
- Translational Molecular Imaging Tool of Vulnerable Carotid Plaque: Evaluate Effects of Statin Therapy on Plaque Inflammation and American Heart Association-Defined Risk Levels in Cuff-Implanted Apolipoprotein E-Deficient Mice.Translational stroke research · 2024Article
- The role of LncRNA LBX2-AS1 in cancers: functions, mechanisms and potential clinical utility.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Optical molecular imaging and theranostics in neurological diseases based on aggregation-induced emission luminogens.European journal of nuclear medicine and molecular imaging · 2022Review
- Biomedical Imaging in Experimental Models of Cardiovascular Disease.Circulation research · 2022Review
- Optical Imaging of Epigenetic Modifications in Cancer: A Systematic Review.Phenomics (Cham, Switzerland) · 2022Review
- Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role ofTheranostics · 2022Review
- PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective.Frontiers in medicine · 2022Review
- SPECT Imaging of Acute Disc Herniation by Targeting Integrin α5β1 in Rat Models.Frontiers in neurology · 2022Article
- Echocardiographic Molecular Imaging of the Effect of Anticytokine Therapy for Atherosclerosis.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2021Article
- Biodegradable Harmonophores for Targeted High-ResolutionACS nano · 2021Article
- Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.Contrast media & molecular imaging · 2021Article
- Article
- Quantifying drug tissue biodistribution by integrating high content screening with deep-learning analysis.Scientific reports · 2020Article
- Multiplexed non-invasive tumor imaging of glucose metabolism and receptor-ligand engagement using dark quencher FRET acceptor.Theranostics · 2020Article
- Assessment of Novel Antioxidant Therapy in Atherosclerosis by Contrast Ultrasound Molecular Imaging.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2018Article
- Imaging techniques in drug development.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Noninvasive imaging has played an increasing role in the process of cardiovascular drug development. This review focuses specifically on the use of molecular imaging, which has been increasingly applied to improve and accelerate certain preclinical steps in drug development, including the identification of appropriate therapeutic targets, evaluation of on-target and off-target effects of candidate therapies, assessment of dose response, and the evaluation of drug or biological biodistribution and pharmacodynamics. Unlike the case in cancer medicine, in cardiovascular medicine, molecular imaging has not been used as a primary surrogate clinical end point for drug approval. However, molecular imaging has been applied in early clinical trials, particularly in phase 0 studies, to demonstrate proof-of-concept or to explain variation in treatment effect. Many of these applications where molecular imaging has been used in drug development have involved the retasking of technologies that were originally intended as clinical diagnostics. With greater experience and recognition of the rich information provided by in vivo molecular imaging, it is anticipated that it will increasingly be used to address the enormous time and costs associated with bringing a new drug to clinical launch.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.